Test Code SCAP Spinocerebellar Ataxia Repeat Expansion Panel, Varies
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Specimen Type: Whole blood
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Molecular Genetics: Neurology Patient Information
3. If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Useful For
Molecular confirmation of clinically suspected spinocerebellar ataxia when a specific subtype isn’t suspected
Special Instructions
Method Name
Polymerase Chain Reaction (PCR)
Reporting Name
Spinocerebellar Ataxia PanelSpecimen Type
VariesSpecimen Minimum Volume
0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Frozen | |||
Refrigerated |
Reject Due To
Specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Spinocerebellar Ataxia Type 1:
Spinocerebellar ataxia type 1 (SCA1) is characterized by progressive ataxia, dysarthria, eventual deterioration of bulbar functions, and ophthalmoplegia. Onset typically occurs in the third to fourth decade of life. Most individuals present with difficulties in gait or slurred speech. SCA1 is caused by an expansion of the CAG (cytosine-adenine-guanine) trinucleotide repeat in the ATXN1 gene. This trinucleotide repeat is polymorphic in the general population, with the number of benign repeats ranging from 6 to 37. The pathogenicity of the repeat is dependent on the presence or absence of CAT (cytosine-adenine-thymine) trinucleotide repeats that interrupt the CAG repeats. Therefore, individuals with 36 to 37 uninterrupted CAG repeats are predisposed to having a child with an expanded allele. In affected individuals, the CAG expansions are greater than 38 uninterrupted CAG repeats or greater than 44 repeats, regardless of the presence or absence of CAT repeat interruptions. The presence of CAT repeats in an individual with 36 to 43 CAG repeats is considered normal and not disease-causing. In contrast, 38 CAG repeats without CAT repeats are of uncertain significance. There is a report of an individual with very last onset SCA1 with 38 CAG repeats. Reduced penetrance has been associated with 44 CAG repeats. As with other trinucleotide repeat disorders, large CAG expansions are associated with earlier onset and a more severe clinical course.
Spinocerebellar Ataxia Type 2:Spinocerebellar ataxia type 2 (SCA2) is characterized by slowly progressive ataxia, dysarthria, and slow saccadic eye movements. The mean age of onset is in the fourth decade, but symptoms may appear from childhood to later adulthood. SCA2 is caused by an expansion of the CAG trinucleotide repeat in the ATXN2 gene. This trinucleotide repeat is polymorphic in the general population, with the number of benign repeats less than 32. However, 29 to 31 heterozygous repeats have been associated with an increased exponential risk for amyotrophic lateral sclerosis (ALS). Additionally, there has been a report of an individual homozygous for 31 repeats with late-onset cerebellar ataxia. In contrast, 27 repeats have been associated with a protective effect for ALS. In affected individuals, the CAG expansion is greater than 34 repeats, with the most common disease-causing alleles having 37 to 39 repeats. Larger CAG expansions are associated with an earlier age of onset but repeat length cannot predict age of onset or disease severity. A CAG expansion of 32 repeats is of unclear clinical significance. Repeats in the 33 to 34 range are associated with reduced penetrance.
Spinocerebellar Ataxia Type 3:
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is characterized by progressive cerebellar ataxia and pyramidal signs. The age of onset is highly variable but most commonly occurs in the second to fifth decade of life. Individuals may present with gait problems, speech difficulties, clumsiness, or visual blurring. SCA3 is caused by an expansion of the CAG trinucleotide repeat in the ATXN3 gene. This trinucleotide repeat is polymorphic in the general population, with the number of benign repeats ranging from 12 to 44. In affected individuals, the CAG expansion ranges from 60 to 87 repeats. A loose correlation exists between repeat length and clinical phenotype. Individuals with 45 to 59 CAG repeats are predisposed to having a child with an expanded allele and may or may not have symptoms themselves. There have been reports of reduced penetrant and nonpenetrant alleles with repeats in this range.
Spinocerebellar Ataxia Type 6:
Spinocerebellar ataxia type 6 (SCA6) is characterized by adult-onset, slowly progressive cerebellar ataxia, dysarthria, and nystagmus. The mean age of onset is 43 to 52 years. Initial symptoms include unsteadiness, stumbling, and imbalance. SCA6 is caused by an expansion of the CAG trinucleotide repeat in the CACNA1A gene. This trinucleotide repeat is polymorphic in the general population, with the number of benign repeats less than 19. In affected individuals, the CAG expansion ranges from 20 to 33 repeats. Larger CAG expansions are associated with an earlier age of onset. A CAG expansion of 19 repeats is of unclear clinical significance. Individuals with 19 CAG repeats are predisposed to having a child with an expanded allele. Additionally, homozygous abnormal expansions have been reported in individuals with younger age of onset and a more severe phenotype.
Spinocerebellar Ataxia Type 7:
Spinocerebellar ataxia type 7 (SCA7) is characterized by progressive cerebellar ataxia, including dysarthria and dysphagia, and con-rod and retinal dystrophy. Onset ranges from infancy to the fifth or sixth decade of life. SCA7 is caused by an expansion of the CAG trinucleotide repeat in the ATXN7 gene. This trinucleotide repeat is polymorphic in the general population, with the number of benign repeats less than 19. In affected individuals, the CAG expansion is greater than 36 repeats. A CAG expansion of 19 to 27 repeats is of unclear clinical significance. Individuals with 28 to 33 repeats are predisposed to having a child with an expanded allele but are unlikely to have symptoms themselves. Thirty-four to 36 repeats are associated with reduced penetrance, and when symptoms do occur, they are more likely to be associated with later onset and a milder phenotype.
Reference Values
SPINOCEREBELLAR ATAXIA TYPE 1
Normal alleles: <36 CAG repeats
Normal alleles with CAT interruptions: 36-43 repeats
Intermediate alleles without CAT interruptions: 36-37 repeats
Uncertain significance: 38 repeats
Expanded alleles without CAT interruptions: >38 CAG repeats
Expanded alleles with CAT interruptions: >43 CAG repeats
SPINOCEREBELLAR ATAXIA TYPE 2
Normal alleles: <32 repeats
Uncertain significance: 31 homozygous and 32 repeats
Reduced penetrance: 33-34 repeats
Expanded alleles: >34 repeats
SPINOCEREBELLAR ATAXIA TYPE 3
Normal alleles: <45 repeats
Intermediate alleles: 45-59 repeats
Expanded alleles: >59 repeats
SPINOCEREBELLAR ATAXIA TYPE 6
Normal alleles: <19 repeats
Intermediate alleles: 19 heterozygous repeats
Uncertain significance: 19 homozygous repeats
Expanded alleles: >19 repeats
SPINOCEREBELLAR ATAXIA TYPE 7
Normal alleles: <19 repeats
Uncertain significance: 19-27 repeats
Intermediate alleles: 28-33 repeats
Reduced penetrance: 34-36 repeats
Expanded alleles: >36 repeats
An interpretive report will be provided.
Day(s) Performed
Monday, Wednesday
Report Available
21 to 28 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81178
81179
81180
81181
81184
81479 (if appropriate for government payers)